

Chemical Safety Practices Recommendations

SCH772984

Exposure Hazards			
<p>Category 2 Warning Toxic</p>  <p>Repeat exposure may cause skin rash, diarrhea, and nausea.(1, 2)</p>	<p>Category 2 Warning</p>  <p>Toxic to Reproduction</p> <p>May harm unborn children.(3)</p>		
Response to Exposure			
Oral	Dermal	Inhalation	Injection
Rinse mouth; do not induce vomiting. Report to OHS.	Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS.	Leave area; go to clean air. Report to OHS.	Report to OHS.
Special Precautions	<p>These statements are based on the literature available for similar drugs. SCH772984 is a novel compound and uncharacterized, the hazards of exposure may be greater than presented and all precautions should be taken to prevent exposure.</p> <p>SCH772984 in DMSO will <u>rapidly</u> penetrate nitrile gloves and skin. Discard garments as hazardous if contaminated with SCH772984.</p>		
Personal Protective Equipment	<p>Gloves (Double glove) (Latex or Nitrile) Skin Protection (Suit or Scrubs or Lab Coat) Eye Protection (Safety-glasses or Goggles) Closed-toe shoes Use N100 respirator if engineering controls are not available.</p>		
Engineering Controls	<p>SCH772984 powder- Chemical Fume Hood (CFH) (4) SCH772984 solution- CFH or Biosafety Cabinet (Class II, B2 BSC if aerosolized)</p> <p style="background-color: yellow;">Animal waste and bedding until 10 days after last treatment- CFH or Class II, B2</p>  <p>BSC</p>		
Animal Handling	Avoid exposure to animal waste/tissue until 10 days after last treatment.		
Bedding Disposal	Dispose of bedding as hazardous material until 10 days after last treatment.		
Work Practices	<p>Empty SCH772984 containers and unused SCH772984 must be disposed of as hazardous.</p> <p>Follow LASP SOPs for preparation, handling, dosing, and disposal of SCH772984.</p>		

Chemical Safety Practices Recommendations

SCH772984

References:

1. Wang D, Boerner SA, Winkler JD, LoRusso PM. Clinical experience of MEK inhibitors in cancer therapy. *Biochimica et biophysica acta*. 2007;1773(8):1248-55.
2. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. *Cancer discovery*. 2013;3(7):742-50.
3. Nadeau V, Charron J. Essential role of the ERK/MAPK pathway in blood-placental barrier formation. *Development (Cambridge, England)*. 2014;141(14):2825-37.
4. National Research Council Committee on Prudent Practices in the L. The National Academies Collection: Reports funded by National Institutes of Health. *Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: Updated Version*. Washington (DC): National Academies Press (US)